Arcturus therapeutics receives fda allowance to proceed with phase 2 study of arct-021 (lunar-cov19) vaccine candidate in the united states

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics receives fda allowance to proceed with phase 2 study of arct-021 (lunar-cov19) vaccine candidate in the united states
ARCT Ratings Summary
ARCT Quant Ranking